MannKind and NRx Pharmaceuticals will work together on a possible inhaled dry powder aviptadil based on MannKind's Technosphere particle technology, the companies have announced. MannKind said that it would conduct the feasibility study at its facility in Danbury, CT, USA. TFF Pharmaceuticals had previously announced that it was conducting a feasibility study to … [Read more...] about NRx, MannKind partner on possible Zyesami aviptadil DPI
News
Relief Therapeutics acquires AdVita Lifescience, gets orphan drug designation for inhaled aviptadil for sarcoidosis
According to Relief Therapeutics, the FDA has granted orphan drug designation for RLF-100 inhaled aviptadil for the treatment of sarcoidosis; RLF-100 is currently in Phase 2 development for that indication. Relief also recently acquired German company AdVita Lifescience, which has been developing inhaled aviptadil for human and veterinary use, with Relief citing the … [Read more...] about Relief Therapeutics acquires AdVita Lifescience, gets orphan drug designation for inhaled aviptadil for sarcoidosis
Sanofi to acquire Translate Bio
Sanofi has agreed to pay approximately $3.2 billion for Translate Bio, which is developing inhaled mRNA therapies for cystic fibrosis, primary ciliary dyskinesia, and pulmonary arterial hypertension in addition to a number of intramuscular mRNA vaccines, including vaccines against COVID-19 and influenza. Sanofi is currently partnered with Translate on the … [Read more...] about Sanofi to acquire Translate Bio
Glenmark acquires rights to market SaNOtize’s nitric oxide nasal spray for COVID-19 in a number of Asian markets
Glenmark Pharmaceuticals has acquired the rights to manufacture and sell SaNOtize's nitric oxide nasal spray (NONS) in India and at least a dozen other markets in Asia for the treatment of COVID-19, the companies have announced. Glenmark expects to be ready to launch the nasal spray as "FabiSpray" in India by the fourth quarter of this year following completion of a … [Read more...] about Glenmark acquires rights to market SaNOtize’s nitric oxide nasal spray for COVID-19 in a number of Asian markets
Satsuma initiates new Phase 3 trial of STS101 intranasal DHE powder for migraine
Satsuma Pharmaceuticals has initiated the SUMMIT Phase 3 trial of its STS101 dihydroergotamine (DHE) nasal powder for the treatment of migraine, the company said. A previous Phase 3 trial of STS101 called EMERGE failed to meet its primary endpoints. Topline data from the SUMMIT trial are expected in the second half of 2022. The SUMMIT trial is expected to enroll … [Read more...] about Satsuma initiates new Phase 3 trial of STS101 intranasal DHE powder for migraine
In vitro tests show Augmenta/TFF dry powder mAb neutralizes SARS-C0V-2 Delta variant
Augmenta Bioworks and TFF Pharmaceuticals have announced that in vitro testing of their AUG-3387 dry powder monoclonal antibody has demonstrated that the mAb neutralizes the SARS-CoV-2 Delta variant, the highly transmissible strain that is currently dominant in numerous countries. In vitro tests had already demonstrated that the mAb could be effective against other … [Read more...] about In vitro tests show Augmenta/TFF dry powder mAb neutralizes SARS-C0V-2 Delta variant
Lannett to market Respirent’s generic of Spiriva Handihaler in the US
According to Lannett, the company has acquired US rights to market Respirents generic of Spiriva Handihaler tiotropium bromide DPI for a 10-year period, the company said. Lannett had already acquired US rights to Respirent's generic versions of Advair Diskus in 2019 and Flovent Diskus in 2020. Lannett CEO Tim Crew commented, "We continue to add drug and device … [Read more...] about Lannett to market Respirent’s generic of Spiriva Handihaler in the US
Positive results for Phase 1 trial of CanSinoBio inhaled COVID-19 vaccine
Results from a Phase 1 trial of an inhaled version of CanSino Biologic's Ad5-nCoV vaccine against COVID-19 have been published online in The Lancet Infectious Diseases. The study enrolled 130 healthy volunteers who got either intramuscular Ad5-nCoV, two doses of aerosolized vaccine, or IM vaccine with an aerosolized booster and found that the nebulized vaccine was … [Read more...] about Positive results for Phase 1 trial of CanSinoBio inhaled COVID-19 vaccine
InnarisBio to develop sol-gel delivery technology for intranasal CNS drugs
Atai Life Sciences and University of Queensland technology transfer company UniQuest have announced the launch of a new company called InnarisBio, which will develop intranasal drug delivery technology for CNS drugs based on sol-gel technology developed by Queensland School of Pharmacy Senior Lecturer Harendra (Harry) Parekh. The sol-gel technology platform involves … [Read more...] about InnarisBio to develop sol-gel delivery technology for intranasal CNS drugs
Inhaled dry powder tamibarotene effective against respiratory viruses in preclinical studies
Preclinical studies by researchers from the LKS Faculty of Medicine at The University of Hong Kong have demonstrated that a dry powder formulation of tamibarotene delivered to the lungs of hamster and mice has broad activity against respiratory viruses, including SARS-CoV-2, MERS-CoV, and influenza A H1N1. Results from the studies were published in Advanced … [Read more...] about Inhaled dry powder tamibarotene effective against respiratory viruses in preclinical studies